« Back to Record
Citation APA

Gallant, J. J., Ward, D., Morales-Ramirez, J., Yan, M., Abram, M. M., Plummer, A., Cheng, A. K., Rhee, M. M., Daar, E. E., Raffi, F., Brinson, C., Ruane, P., Dejesus, E., Johnson, M., Clumeck, N., & Osiyemi, O. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The lancet. HIV, 3(4), e158-e165. doi:10.1016/S2352-3018(16)00024-2


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/236157

Gallant, J. J., Ward, D., Morales-Ramirez, J., Yan, M., Abram, M. M., Plummer, A., Cheng, A. K., Rhee, M. M., Daar, E. E., Raffi, F., Brinson, C., Ruane, P., Dejesus, E., Johnson, M., Clumeck, N., & Osiyemi, O. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The lancet. HIV, 3(4), e158-e165. doi:10.1016/S2352-3018(16)00024-2